News

Be Biopharma, Inc. announced the closing of its $92M Series C financing. The round includes participation from new investor Nextech with existing investors including ARCH Venture…
Read More...

REGENXBIO Inc. and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced a strategic partnership for the development and commercialization of RGX-121 for the treatment of…
Read More...

Acadia Pharmaceuticals Inc. announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the treatment…
Read More...

Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Biologics License Application (BLA) for lecanemab-irmb (U.S. brand name:…
Read More...

Daiichi Sankyo Company, Ltd announced that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-associated mucin-1 (TA-MUC1) antibody,…
Read More...

Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, announced the closing of a $100 million…
Read More...

Solid Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SGT-212 for the treatment of…
Read More...

Dizal, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the U.S. Food and Drug Administration…
Read More...

Amgen announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to IMDYLLTRA for the treatment of adult…
Read More...

Variant Bio, a genomics-driven drug discovery company, announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic disease.…
Read More...

Tempest Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to amezalpat (TPST-1120), an oral, small molecule,…
Read More...

Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group"), and Fortress Biotech, Inc. ("Fortress")…
Read More...

Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases,…
Read More...

GSK plc announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate (ADC)…
Read More...

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultrarare genetic diseases, announced that…
Read More...

GSK plc announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on…
Read More...

LPOXY Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on innovative therapies for infectious disease prevention, announced that it has signed a term sheet to…
Read More...

Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs announced that it has entered…
Read More...

Astellas Pharma Inc. announced that China's National Medical Products Administration (NMPA) has approved VYLOY™ (zolbetuximab), in combination with fluoropyrimidine- and…
Read More...

Seres Therapeutics, Inc. (Seres or the Company) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SER-155, the Company’s lead…
Read More...